Response of Treatment of Hepatitis B in Children-A Case Series from IndiaIra Shah*
Department of Pediatric Hepatobiliary Clinic, B. J. Wadia Hospital for Children Parel, Mumbai-400012, India
- *Corresponding Author:
- Ira Shah
Department of Pediatric Hepatobiliary Clinic
B. J. Wadia Hospital for Children Parel
Tel: +91-22- 23693509
E-mail: [email protected]
Received date: November 24, 2016; Accepted date: December 29, 2016; Published date: January 05, 2017
Citation: Shah I (2016) Response of Treatment of Hepatitis B in Children-A Case Series from India. J Liver 6: 206. doi: 10.4172/2167-0889.1000206
Copyright: ©2016 Shah I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Chronic Hepatitis B virus (HBV) infection is a major cause of liver disease leading to cirrhosis and hepatocellular carcinoma. Children are more likely to develop chronic HBV infection. Treatment with Interferon alfa (IFN-α), lamivudine (3TC) or adefovir are recommended in children with chronic active HBV with replicating virus. We present a series of 7 patients treated with combination IFN-α (5-10 million units/m² subcutaneously thrice a week)+3TC (4 mg/kg/day, not exceeding 100 mg/day) for 6 months and additional 3TC for 6 months alone). Of the 7 patients, one patient had complete response and viral load remained suppressed even after 2 years of therapy and remaining 6 patients had partial response (viral load became undetectable, but ‘e’ antigen remained positive). Thus we concluded that the antiviral treatment in children while effective remains partial as the reappearance of HBV DNA at variable time after stopping therapy can still occur.